Evidence map›Paper›PMID 28856115›Full record

ArticlePsoriasis (Auckland, N.Z.)2016

Erythrodermic psoriasis: pathophysiology and current treatment perspectives.

Rasnik K Singh, Kristina M Lee, Derya Ucmak, Merrick Brodsky, Zaza Atanelov, Benjamin Farahnik, Michael Abrouk, Mio Nakamura, Tian Hao Zhu, Wilson Liao

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Psoriasis (Auckland, N.Z.), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 74 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
74citing papers in PubMed, 2 pooled it
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

74 citing papers in PubMed, 2 syntheses or guidelines pooled it, 124 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Article
  7. The theory of the inflammatory ecosystem.Science China. Life sciences · 2026
    Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review

14 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 1 country.

Rasnik K SinghDepartment of Medicine, University of California - Los Angeles, David Geffen School of Medicine, Los Angeles.
Kristina M LeeDepartment of Dermatology, University of California - San Francisco, San Francisco.
Derya UcmakDepartment of Dermatology, University of California - San Francisco, San Francisco.
Merrick BrodskyDepartment of Medicine, University of California - Irvine, School of Medicine, Irvine, CA.
Zaza AtanelovDepartment of Medicine, New York Medical College, Valhalla, NY.
Benjamin FarahnikDepartment of Medicine, University of Vermont College of Medicine, Burlington, VT.
Michael AbroukDepartment of Medicine, University of California - Irvine, School of Medicine, Irvine, CA.
Mio NakamuraDepartment of Dermatology, University of California - San Francisco, San Francisco.
Tian Hao ZhuDepartment of Medicine, University of Southern California Keck School of Medicine, Los Angeles, CA, USA.
Wilson LiaoDepartment of Dermatology, University of California - San Francisco, San Francisco.
University of California, San Francisco · USUniversity of California, Irvine · USNew York Medical College · USUniversity of California, Los Angeles · USUniversity of Southern California · USUniversity of Vermont · US

Funding

MHC and KIR Region Genomics in PsoriasisU01AI119125 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI LIAO, WILSON · 2015 to 2019
$3.5M
Identification of Causal Variants in PsoriasisR01AR065174 · NIAMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI LIAO, WILSON · 2013 to 2016
$1.8M
NIAID NIH HHS U01 AI119125NIAMS NIH HHS R01 AR065174
6 · The paper itself

Abstract

Erythrodermic psoriasis (EP) is a rare and severe variant of psoriasis vulgaris, with an estimated prevalence of 1%-2.25% among psoriatic patients. The condition presents with distinct histopathologic and clinical findings, which include a generalized inflammatory erythema involving at least 75% of the body surface area. The pathogenesis of EP is not well understood; however, several studies suggest that the disease is associated with a predominantly T helper 2 (Th2) phenotype. Given the morbidity and potential mortality associated with the condition, there is a need for a better understanding of its pathophysiology. The management of EP begins with a comprehensive assessment of the patient's presentation and often requires multidisciplinary supportive measures. In 2010, the medical board of the US National Psoriasis Foundation published consensus guidelines advocating the use of cyclosporine or infliximab as first-line therapy in unstable cases, with acitretin and methotrexate reserved for more stable cases. Since the time of that publication, additional information regarding the efficacy of newer agents has emerged. We review the latest data with regard to the treatment of EP, which includes biologic therapies such as ustekinumab and ixekizumab.

Indexed as

biologicsEPerythrodermic psoriasispathogenesispathophysiologytreatment

Identifiers

PMID28856115
PMCPMC5572467
OpenAlexW2490107668

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.